Prostate Cancer

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The systemic treatment of prostate cancer has evolved to feature interference with androgen signaling that fuels malignant cancer cell growth and progression, the possible early use of taxane chemotherapy, the availability of bone-targeted agents that reduce skeletal complications of metastatic disease and its treatment, and the emergence of various immunotherapies. New drug development has seen nine new agents approved for prostate cancer over a little more than a decade. Molecular insights into prostatic carcinogenesis and life-threatening prostate cancer progression are illuminating new opportunities for treatment development and refinement, defining mechanisms of treatment sensitivity and resistance. Hopefully, prostate cancer deaths, which have been on the decline for several years, can eventually be eliminated with new treatments and new treatment strategies.

Original languageEnglish (US)
Title of host publicationTargeted Therapy in Translational Cancer Research
PublisherWiley Blackwell
Pages273-286
Number of pages14
ISBN (Electronic)9781118468678
ISBN (Print)9781118468579
DOIs
StatePublished - Oct 30 2015

Fingerprint

Prostatic Neoplasms
Therapeutics
Immunotherapy
Androgens
Carcinogenesis
Bone and Bones
Drug Therapy
Growth
Pharmaceutical Preparations
Neoplasms

Keywords

  • Androgen deprivation
  • Androgen receptor
  • Anti-androgen
  • Bisphosphonate
  • Prostate cancer
  • Taxane

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Nelson, W. G., Haffner, M. C., & Yegnasubramanian, S. (2015). Prostate Cancer. In Targeted Therapy in Translational Cancer Research (pp. 273-286). Wiley Blackwell. https://doi.org/10.1002/9781118468678.ch28

Prostate Cancer. / Nelson, William G; Haffner, Michael C.; Yegnasubramanian, S.

Targeted Therapy in Translational Cancer Research. Wiley Blackwell, 2015. p. 273-286.

Research output: Chapter in Book/Report/Conference proceedingChapter

Nelson, WG, Haffner, MC & Yegnasubramanian, S 2015, Prostate Cancer. in Targeted Therapy in Translational Cancer Research. Wiley Blackwell, pp. 273-286. https://doi.org/10.1002/9781118468678.ch28
Nelson WG, Haffner MC, Yegnasubramanian S. Prostate Cancer. In Targeted Therapy in Translational Cancer Research. Wiley Blackwell. 2015. p. 273-286 https://doi.org/10.1002/9781118468678.ch28
Nelson, William G ; Haffner, Michael C. ; Yegnasubramanian, S. / Prostate Cancer. Targeted Therapy in Translational Cancer Research. Wiley Blackwell, 2015. pp. 273-286
@inbook{444ec08f0cf247a98bc70fa63ffd14e1,
title = "Prostate Cancer",
abstract = "The systemic treatment of prostate cancer has evolved to feature interference with androgen signaling that fuels malignant cancer cell growth and progression, the possible early use of taxane chemotherapy, the availability of bone-targeted agents that reduce skeletal complications of metastatic disease and its treatment, and the emergence of various immunotherapies. New drug development has seen nine new agents approved for prostate cancer over a little more than a decade. Molecular insights into prostatic carcinogenesis and life-threatening prostate cancer progression are illuminating new opportunities for treatment development and refinement, defining mechanisms of treatment sensitivity and resistance. Hopefully, prostate cancer deaths, which have been on the decline for several years, can eventually be eliminated with new treatments and new treatment strategies.",
keywords = "Androgen deprivation, Androgen receptor, Anti-androgen, Bisphosphonate, Prostate cancer, Taxane",
author = "Nelson, {William G} and Haffner, {Michael C.} and S Yegnasubramanian",
year = "2015",
month = "10",
day = "30",
doi = "10.1002/9781118468678.ch28",
language = "English (US)",
isbn = "9781118468579",
pages = "273--286",
booktitle = "Targeted Therapy in Translational Cancer Research",
publisher = "Wiley Blackwell",

}

TY - CHAP

T1 - Prostate Cancer

AU - Nelson, William G

AU - Haffner, Michael C.

AU - Yegnasubramanian, S

PY - 2015/10/30

Y1 - 2015/10/30

N2 - The systemic treatment of prostate cancer has evolved to feature interference with androgen signaling that fuels malignant cancer cell growth and progression, the possible early use of taxane chemotherapy, the availability of bone-targeted agents that reduce skeletal complications of metastatic disease and its treatment, and the emergence of various immunotherapies. New drug development has seen nine new agents approved for prostate cancer over a little more than a decade. Molecular insights into prostatic carcinogenesis and life-threatening prostate cancer progression are illuminating new opportunities for treatment development and refinement, defining mechanisms of treatment sensitivity and resistance. Hopefully, prostate cancer deaths, which have been on the decline for several years, can eventually be eliminated with new treatments and new treatment strategies.

AB - The systemic treatment of prostate cancer has evolved to feature interference with androgen signaling that fuels malignant cancer cell growth and progression, the possible early use of taxane chemotherapy, the availability of bone-targeted agents that reduce skeletal complications of metastatic disease and its treatment, and the emergence of various immunotherapies. New drug development has seen nine new agents approved for prostate cancer over a little more than a decade. Molecular insights into prostatic carcinogenesis and life-threatening prostate cancer progression are illuminating new opportunities for treatment development and refinement, defining mechanisms of treatment sensitivity and resistance. Hopefully, prostate cancer deaths, which have been on the decline for several years, can eventually be eliminated with new treatments and new treatment strategies.

KW - Androgen deprivation

KW - Androgen receptor

KW - Anti-androgen

KW - Bisphosphonate

KW - Prostate cancer

KW - Taxane

UR - http://www.scopus.com/inward/record.url?scp=85015908568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015908568&partnerID=8YFLogxK

U2 - 10.1002/9781118468678.ch28

DO - 10.1002/9781118468678.ch28

M3 - Chapter

AN - SCOPUS:85015908568

SN - 9781118468579

SP - 273

EP - 286

BT - Targeted Therapy in Translational Cancer Research

PB - Wiley Blackwell

ER -